» Articles » PMID: 38256597

Unveiling the Heart of the Matter: Echocardiographic Insights into Diastolic Function and Left Ventricular and Atrial Changes in HIV Patients with Controlled Viremia

Overview
Journal J Clin Med
Specialty General Medicine
Date 2024 Jan 23
PMID 38256597
Authors
Affiliations
Soon will be listed here.
Abstract

Background: People living with human immunodeficiency virus (HIV) (PLWH) have increased risk of developing diastolic dysfunction (DD) and heart failure with preserved ejection fraction (EF). In this observational study, we evaluated DD and left ventricular hypertrophy (LVH) in PLWH receiving antiretroviral therapy (ART) with undetectable viremia.

Methods: We conducted an observational study. All participants underwent transthoracic echocardiography to assess chamber size and systolic and diastolic function.

Results: Most patients showed concentric remodeling without LVH. All patients had normal left ventricle systolic function (EF median 61.3%, interquartile range: 57.8-66.2). None fulfilled the DD criteria, while two patients (6%) had undetermined diastolic function. Twenty percent ( = 7) of patients had an enlarged left atrium (left atrium volume index [LAVI] > 34 cm/m). These patients had a significantly lower CD4 count (771.53 ± 252.81 vs. 446.00 ± 219.02, = 0.01) and higher relative wall thickness (0.50 ± 0.05 vs. 0.44 ± 0.06, = 0.03). Patients without immune restoration above 500 cells/μL had significantly higher LAVI (33.92 ± 6.63 vs. 24.91 ± 7.03, = 0.01).

Conclusions: One-fifth of patients had left atrial enlargement associated with worse immune restoration during ART treatment. The mechanism of left atrial enlargement and its association with cardiovascular risk require further investigations.

Citing Articles

Depressive Symptoms and Left Ventricular Diastolic Dysfunction Among Men and Women with HIV.

Martinez C, Haw N, Rodriguez V, Kizer J, Post W, Wu K Eur Med J Cardiol. 2025; 12(1):106-120.

PMID: 39936004 PMC: 11812528. DOI: 10.33590/emjcardiol/AKTG4946.


Cardiovascular Risk in People Living with Human Immunodeficiency (HIV) Viremia Suppression in a Young, Mid-Eastern European Population - Preliminary Study.

Jachymek M, Wojcik L, Peregud-Pogorzelska M, Parczewski M, Dembowska A, Aksak-Was B Vasc Health Risk Manag. 2024; 20:435-445.

PMID: 39324108 PMC: 11423823. DOI: 10.2147/VHRM.S472328.

References
1.
Visseren F, Mach F, Smulders Y, Carballo D, Koskinas K, Back M . 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021; 42(34):3227-3337. DOI: 10.1093/eurheartj/ehab484. View

2.
Biton Y, Goldenberg I, Kutyifa V, Baman J, Solomon S, Moss A . Relative Wall Thickness and the Risk for Ventricular Tachyarrhythmias in Patients With Left Ventricular Dysfunction. J Am Coll Cardiol. 2016; 67(3):303-12. DOI: 10.1016/j.jacc.2015.10.076. View

3.
Arodiwe I, Eke C, Arodiwe E . Left ventricular hypertrophy in African children infected with HIV/AIDS: a case-control study. Pan Afr Med J. 2023; 45:110. PMC: 10504446. DOI: 10.11604/pamj.2023.45.110.37095. View

4.
Yamaguchi S, Shimabukuro M, Abe M, Arakaki T, Arasaki O, Ueda S . Comparison of the prognostic values of three calculation methods for echocardiographic relative wall thickness in acute decompensated heart failure. Cardiovasc Ultrasound. 2019; 17(1):30. PMC: 6891973. DOI: 10.1186/s12947-019-0179-6. View

5.
Okeke N, Alenezi F, Bloomfield G, Dunning A, Clement M, Shah S . Determinants of Left Ventricular Hypertrophy and Diastolic Dysfunction in an HIV Clinical Cohort. J Card Fail. 2018; 24(8):496-503. PMC: 6231907. DOI: 10.1016/j.cardfail.2018.06.003. View